|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) |
|---|---|
| Information provided by: | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) |
| ClinicalTrials.gov Identifier: | NCT00065949 |
Purpose
Premature infants are at risk for acute brain injuries and long-term developmental problems such as cerebral palsy (CP). Research suggests that high levels of magnesium at and around the time of birth may decrease the risk of brain injuries. This study will evaluate the effects of giving magnesium to premature infants.
| Condition | Intervention | Phase |
|---|---|---|
|
Brain Injuries Cerebral Palsy |
Drug: magnesium sulfate |
Phase III |
| Study Type: | Interventional |
| Study Design: | Prevention, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study |
| Official Title: | Magnesium Prevention of Brain Injury in Preterm Infants |
| Study Start Date: | August 1987 |
| Estimated Study Completion Date: | February 2003 |
Premature infants weighing less than 1500 grams (3.3 lbs) represent approximately 1.3% of liveborn infants, yet comprise at least 25% of all children who are subsequently diagnosed with CP. Antepartum exposure to magnesium (Mg) may prevent or ameliorate early brain injury (intracranial hemorrhage and cystic periventricular leukomalacia), as well as long-term adverse neurodevelopmental outcomes (CP and mental retardation) in very low birthweight (VLBW) preterm infants. In preliminary studies, short- and long-term neuroprotection were associated with initial serum Mg levels above 3.0 mEq/L. This study will determine whether early abnormal neurosonographic findings and long-term adverse neurodevelopmental outcomes in VLBW premature infants are influenced by different levels of serum Mg achieved during the first week of life.
Infants will be randomized to either "standard" Mg therapy or "high" Mg therapy. Standard Mg therapy consists of no supplemental Mg for the first 3 days of life followed by intravenous magnesium sulfate (MgSO4) aimed at attaining serum Mg levels in the normal range of 1.2-2.3 mEq/L. High Mg therapy consists of using intravenous MgSO4 to maintain higher (nonharmful) serum Mg levels between 3.5-5.5 mEq/L for the first 3 days of life and between 2.5-3.5 mEq/L for the next 4 days. The high Mg infants will subsequently have their serum Mg levels maintained at 2.4+0.3 mEq/L using oral magnesium gluconate for the remainder of their neonatal hospitalization.
Infants will be evaluated for early brain injury with head ultrasound studies 12 to 24 hours after birth, at 2 to 3 day intervals while ventilator support is required, and at weekly intervals until discharge. The infants will subsequently be assessed in the high-risk follow-up clinic for a minimum of 24 months (corrected for degree of prematurity). At 24 months of age, they will be evaluated by a pediatric neurologist for the presence of cerebral palsy. They will be tested serially for problems in early cognition (mental, language, and perceptual ability), as well as fine and gross motor skills.
Eligibility| Ages Eligible for Study: | up to 12 Hours |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria
Exclusion Criteria
Contacts and Locations| United States, Pennsylvania | |
| Thomas Jefferson University | |
| Philadelphia, Pennsylvania, United States, 19107 | |
| Principal Investigator: | Thomas E. Wiswell, M.D. | Thomas Jefferson University |
More Information
| Study ID Numbers: | HD21453, NICHD-13, NICHD-0523, 5 RO1 HD21453 |
| Study First Received: | August 1, 2003 |
| Last Updated: | June 23, 2005 |
| ClinicalTrials.gov Identifier: | NCT00065949 History of Changes |
| Health Authority: | United States: Federal Government |
|
Low birthweight infants Magnesium supplementation Intracranial hemorrhage Cystic periventricular leukomalacia Mental retardation |
|
Craniocerebral Trauma Molecular Mechanisms of Pharmacological Action Magnesium Sulfate Brain Damage, Chronic Physiological Effects of Drugs Disorders of Environmental Origin Anesthetics Calcium Channel Blockers Reproductive Control Agents Brain Diseases Membrane Transport Modulators Cerebral Palsy Tocolytic Agents Sensory System Agents |
Therapeutic Uses Analgesics Anti-Arrhythmia Agents Brain Injuries Nervous System Diseases Wounds and Injuries Central Nervous System Diseases Central Nervous System Depressants Trauma, Nervous System Cardiovascular Agents Pharmacologic Actions Peripheral Nervous System Agents Central Nervous System Agents Anticonvulsants |